問卷

TPIDB > Search Result

Search Result

篩選

List

46Cases

2025-01-21 - 2030-12-31

Phase I/II

Active
A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors
  • Condition/Disease

    Advanced Solid Tumors 、Malignant Neoplasm

  • Test Drug

    Freeze-dried injection

Participate Sites
3Sites

Recruiting3Sites

2025-08-01 - 2035-08-31

Phase III

Not yet recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Mevrometostat (PF-06821497) With Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (MEVPRO-3)
  • Condition/Disease

    Metastatic Castration Sensitive Prostate Cancer (mCSPC)

  • Test Drug

    Tablets Capsules

Participate Sites
6Sites

Recruiting6Sites

2025-11-01 - 2031-07-31

Phase III

Active
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
  • Condition/Disease

    Metastatic Castration-resistant Prostate Cancer

  • Test Drug

    Frozen Crystal Injection Injection Injection Lumps Lumps Lumps

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2025-06-18 - 2027-12-31

Phase I

Not yet recruiting
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
  • Condition/Disease

    Neoplasms

  • Test Drug

    Injectable

Participate Sites
6Sites

Recruiting6Sites

2024-10-01 - 2035-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2022-05-01 - 2024-08-16

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-11-01 - 2031-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-10-01 - 2029-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2021-12-30 - 2027-04-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2021-12-04 - 2024-09-30

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 2 3 4 5